BRPI0514469A - moduladores de androgênio - Google Patents

moduladores de androgênio

Info

Publication number
BRPI0514469A
BRPI0514469A BRPI0514469-8A BRPI0514469A BRPI0514469A BR PI0514469 A BRPI0514469 A BR PI0514469A BR PI0514469 A BRPI0514469 A BR PI0514469A BR PI0514469 A BRPI0514469 A BR PI0514469A
Authority
BR
Brazil
Prior art keywords
androgen
modulators
androgen modulators
compound
phenoxy
Prior art date
Application number
BRPI0514469-8A
Other languages
English (en)
Inventor
Bruce Allen Lefker
Yvonne Dorothy Smith
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BRPI0514469A publication Critical patent/BRPI0514469A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

MODULADORES DE ANDROGêNIO. A presente invenção refere-se a um composto 4-(2-metóxi-fenóxi)-2-trifluorometil-benzonitrila, a seu uso como um modulador de androgênio e a composições farmacêuticas contendo este composto.
BRPI0514469-8A 2004-08-18 2005-08-05 moduladores de androgênio BRPI0514469A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60256004P 2004-08-18 2004-08-18
PCT/IB2005/002832 WO2006018732A1 (en) 2004-08-18 2005-08-05 Androgen modulators

Publications (1)

Publication Number Publication Date
BRPI0514469A true BRPI0514469A (pt) 2008-06-10

Family

ID=35478214

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514469-8A BRPI0514469A (pt) 2004-08-18 2005-08-05 moduladores de androgênio

Country Status (7)

Country Link
US (1) US20080064745A1 (pt)
EP (1) EP1781599A1 (pt)
JP (1) JP2008509986A (pt)
BR (1) BRPI0514469A (pt)
CA (1) CA2573457A1 (pt)
MX (1) MX2007001248A (pt)
WO (1) WO2006018732A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1737813A1 (en) 2004-04-13 2007-01-03 Warner-Lambert Company LLC Androgen modulators
JP2007533726A (ja) 2004-04-22 2007-11-22 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アンドロゲンモジュレーター
EP1781598A1 (en) 2004-07-08 2007-05-09 Warner-Lambert Company LLC Androgen modulators
US20090105349A1 (en) * 2004-08-18 2009-04-23 Warner-Lambert Company Llc Androgen modulators
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1741761A (en) * 1923-11-08 1929-12-31 Merck & Co Inc Quinine compound and process of making the same
US4029493A (en) * 1973-02-23 1977-06-14 Mobil Oil Corporation Substituted phenoxybenzonitriles as herbicides
FR2397387A1 (fr) * 1976-04-27 1979-02-09 Serobiologiques Lab Sa 4,4'-bis-formyl-polyhalo-diphenoxyalcanes, procede de preparation et application a la synthese de 4,4'-dicyano-polyhalo-diphenoxyalcanes
US4234595A (en) * 1977-07-13 1980-11-18 Mead Johnson & Company 3-Indolyl-tertiary butylaminopropanols
EP0107759B1 (de) * 1982-08-26 1992-12-16 MERCK PATENT GmbH Cyclohexanderivate und ihre Verwendung als Komponenten Flüssigkristalliner-Dielektrika
US4536321A (en) * 1983-02-18 1985-08-20 Chisso Corporation Fluorobenzene derivatives and liquid crystal compositions containing the same
US4992433A (en) * 1987-11-23 1991-02-12 Janssen Pharmaceutica N.V. Novel pyridazinamine derivatives
US5316755A (en) * 1993-02-02 1994-05-31 Sterling Winthrop Inc. Compositions of iodophenoxy alkanes and iodophenyl ethers for visualization of the gastrointestinal tract
TW262553B (pt) * 1994-03-17 1995-11-11 Hitachi Seisakusyo Kk
DE19534209A1 (de) * 1995-09-15 1997-03-20 Jenapharm Gmbh Hormonales Mittel zur Behandlung der Haut
ES2127106B1 (es) * 1996-03-21 1999-11-16 Menarini Lab Derivados benzopiranicos con accion antagonista de los leucotrienos, procedimiento para su preparacion y utilizacion de los mismos.
US5847166A (en) * 1996-10-10 1998-12-08 Massachusetts Institute Of Technology Synthesis of aryl ethers
US5800624A (en) * 1996-10-22 1998-09-01 University Of Notre Dame Membrane process for separating carbohydrates
US6071957A (en) * 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
US7060331B2 (en) * 2000-07-13 2006-06-13 Merck Patent Gmbh Chiral compounds 1
US6933321B2 (en) * 2002-02-15 2005-08-23 Endorecherche, Inc. Antiandrogenic biphenyls
KR20040104463A (ko) * 2002-02-28 2004-12-10 유니버시티 오브 테네시 리서치 파운데이션 비가역적 선택적 안드로겐 수용체 모듈레이터 및 이를사용하는 방법
US6875438B2 (en) * 2002-04-27 2005-04-05 Aventis Pharma Deutschland Gmbh Preparations for topical administration of substances having antiandrogenic activity
KR100783255B1 (ko) * 2004-02-13 2007-12-06 워너-램버트 캄파니 엘엘씨 안드로젠 수용체 조절제
EP1781598A1 (en) * 2004-07-08 2007-05-09 Warner-Lambert Company LLC Androgen modulators
US20090105349A1 (en) * 2004-08-18 2009-04-23 Warner-Lambert Company Llc Androgen modulators

Also Published As

Publication number Publication date
WO2006018732A1 (en) 2006-02-23
EP1781599A1 (en) 2007-05-09
CA2573457A1 (en) 2006-02-23
JP2008509986A (ja) 2008-04-03
US20080064745A1 (en) 2008-03-13
MX2007001248A (es) 2007-03-23

Similar Documents

Publication Publication Date Title
UY31274A1 (es) Composiciones de recubrimiento electrodepositable que contiene una guanidina ciclica
UA112281C2 (uk) Стабільні інсектицидні композиції і способи їх отримання
DOP2009000235A (es) Aril pirrolidinas insecticidas
ECSP10010722A (es) Compuestos orgánicos
CR9346A (es) Celulas estromaticas de adulto derivadas de tejido adiposo que exhiben caracteristicas de celulas endoteliales
BR112012014082A2 (pt) composições e métodos que compreendem variantes de protease
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
DK2134691T3 (da) Quinolinonderivativer som parp- og tank-inhibitorer
DK1778236T3 (da) Modificerede pyrimidin-glucocorticoid-receptor-modulatorer
CR9081A (es) Inhibidores de la interaccion entre mdm2 y p53
GT200800276A (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
ECSP11010812A (es) Complejo de mineral-aminoácido polisacárido
SV2009003221A (es) Composiciones de fenilalquilamino carbamato ref. prd2743svpct
NO20060021L (no) Trelim
ES2422275T3 (es) Derivado del oxindol sustituido y su uso como un modulador del receptor de la vasopresina
ATE459620T1 (de) Benzimidazolthiophenverbindungen als plk- modulatoren
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
PA8796901A1 (es) Inhibidores de la interaccion entre mdm2 y p53
BRPI0620229A8 (pt) formulação
UY31688A1 (es) Plaguicidas
GT200600414A (es) Sal de glucuranato de compuesto de piperazine
UY30451A1 (es) 18-metil-19-nor-androst-4-en-17,17-espiroéteres (18-metil-19-nor-20-espirox-4-en-3-onas),ase como preparaciones farmacéuticas que lo contienen.
WO2010054286A3 (en) Substituted hydroxyphenylamine compounds
BRPI0514469A (pt) moduladores de androgênio
TR201906145T4 (tr) Faktör VII bileşimi.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.